China-based Contract Research Organization (CRO) GenScript Biotech Corporation (HKG: 1548) has announced that its subsidiary, Legend Biotech Corporation (NASDAQ: LEGN), has reported sales of USD 117 million for its BCMA-directed chimeric antigen receptor T cell (CAR-T) therapy, Carvykti (ciltacabtagene autoleucel), as of June 30, 2023. The sales data, provided by partner Janssen Biotech, a subsidiary of Johnson & Johnson, is pending independent audit.
Global Commercialization and Market Approvals
The drug is currently being commercialized in the US, Europe, and other global markets by Janssen Biotech. Carvykti received its first major market approvals last year, beginning with the US in March, followed by the European Medicines Agency (EMA) in May, and Japan. The therapy is indicated for heavily pre-treated patients with relapsed/refractory multiple myeloma (MM). The drug is now awaiting its first regulatory decision in China, marking a significant milestone in its global expansion.
Impact of Carvykti on the CAR-T Therapy Market
The strong sales figures for Carvykti highlight the growing demand for innovative CAR-T therapies in the treatment of multiple myeloma. As the therapy awaits regulatory decisions in additional markets, its potential to transform patient outcomes continues to gain recognition. The partnership between Legend Biotech and Janssen Biotech underscores the importance of collaboration in bringing cutting-edge treatments to patients worldwide.-Fineline Info & Tech
